Overview
Portfolio
More
Mountpleasant Ventures
Washington, United States
Provides angel investment and patient capital to early‑stage biotech and AI companies, prioritizing sustainable growth over rapid exits.
Portfolio
11+
Employees
3+
Founded
N/A
AUM
N/A
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
United States
Sources
Mountpleasant Ventures
Provides angel investment and patient capital to early‑stage biotech and AI companies, prioritizing sustainable growth over rapid exits.
Portfolio
11+
Employees
3+
Founded
N/A
AUM
N/A
Stages
No stages listed
Industries
No industries listedGeographic scope
United States
Sources
Showing 7 of 7 matched portfolio companies
Curebase provides decentralized clinical research software that enables efficient data collection through electronic patient-reported outcomes (ePRO) and electronic consent (eConsent) systems. The platform enhances participant engagement and accelerates study launches while ensuring high-quality data capture across diverse clinical trials.
Funding: $57.6M
Rough estimate of the amount of funding raised
Funding: $57.6M
Rough estimate of the amount of funding raised
Eigen develops combination therapies that modulate target expression in cancer cells to enhance the efficacy of existing targeted treatments while minimizing toxicity. Their platform utilizes machine learning and high-throughput screening to create co-therapies that improve patient eligibility and reduce relapse rates across diverse cancer types.
Funding: $7.0M
Rough estimate of the amount of funding raised
Funding: $7.0M
Rough estimate of the amount of funding raised
Floreo provides a virtual‑reality therapy platform that delivers research‑backed social‑skill lessons for neurodiverse learners of any age. Accessible via smartphone‑plus‑cardboard or standalone VR headsets, the system offers immersive, repeatable practice, real‑time coaching, and cloud‑based analytics that integrate with telehealth workflows, enabling clinicians, schools, and families to deliver scalable, evidence‑based skill training.
Opentrons develops the Flex, a versatile pipetting robot that automates liquid handling tasks in laboratory settings, allowing for precise transfers of 1 to 1000 μL using swappable pipettes. This technology addresses the inefficiencies of manual pipetting by enabling rapid setup and execution of experiments, thereby increasing throughput and reducing the potential for human error.
Funding: $240.0M
Rough estimate of the amount of funding raised
Funding: $240.0M
Rough estimate of the amount of funding raised
The startup develops stem cell-based therapies that target leukemia, blood diseases, and tissue damage through bioengineering techniques. Their solutions enhance organ transplantation outcomes and mitigate the effects of radiation poisoning, ultimately improving patient health and longevity.
Phase Genomics develops ultra-long-range genome sequencing technology and computational tools that enable the assembly of complete and accurate genomes and metagenomes without the need for cultivation. This platform addresses the challenge of obtaining high-resolution genomic data, facilitating breakthroughs in agriculture, human health, and industrial biology.
Funding: $5.8M
Rough estimate of the amount of funding raised
Funding: $5.8M
Rough estimate of the amount of funding raised
Sorcero's Language Intelligence Platform utilizes medically-tuned AI to unify and analyze structured and unstructured medical data, enabling teams to extract actionable insights for informed decision-making. The platform addresses the challenge of rapidly identifying relevant safety signals and optimizing treatment strategies, significantly enhancing productivity and accuracy in medical affairs and regulatory processes.
Funding: $5.1M
Rough estimate of the amount of funding raised
Funding: $5.1M
Rough estimate of the amount of funding raised
Showing 4 of 4 unmatched portfolio companies